Cerulean Pharma Named One of the “Fierce 15” Leading Biotech Companies of 2011

Chief Executive Officer Oliver Fetzer, Ph.D., to Showcase Company Progress at BioPharm America 2011™

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced that FierceBiotech has named the Company one of 2011’s Fierce 15 companies, designating it as one of the most promising private biotechnology companies in the industry.

“After growing up from its nanotechnology roots at Caltech as well as MIT, Cerulean is well into its mid-stage development phase, eyeing data on the efficacy and safety of a new approach to delivering cancer drugs,” said John Carroll, editor in chief of FierceBiotech. “The Company is putting its technology to the test in the clinic with its CRLX101 nanopharmaceutical by seeing if it can make a harshly toxic molecule useful against non-small cell lung cancer.”

“Anyone familiar with the preclinical drug development scene will be aware of the promise of nanotechnology,” Carroll added. “For years now, scientists in the lab have been advancing the ‘science of small’ to repackage therapeutics into tiny delivery vehicles that can more precisely target a disease. On top of their clinical and preclinical cancer drug programs, the scientists at Cerulean are working on technology that may help reenergize the RNAi field, potentially offering a better approach for delivery and clearing a serious development roadblock which has stymied a slate of companies and spurred some Big Pharma companies to shelve once ambitious programs. That’s a lot for a mid-sized biotech. In fact, for a small developer with 25 staffers, it’s remarkable progress.”

“It is an honor to have been selected by the editors of FierceBiotech to be part of Fierce 15 class of 2011,” said Oliver Fetzer, Ph.D., chief executive officer of Cerulean. “2011 has been an exciting year for us. Our clinical team is firing on all cylinders and is rapidly recruiting our randomized Phase 2 study of CRLX101 in advanced non-small cell lung cancer. At the same time, our research team has assembled a powerful data set showing that we have the potential to extend the application of our platform from small molecules to large molecules, such as siRNA and peptides. On all fronts, we believe we are fulfilling our mission of advancing new classes of nanotechnology-based therapies to fundamentally improve patient outcomes.”

An internationally recognized daily newsletter reaching more than 90,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick, authoritative briefing on the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies before compiling the Fierce 15 list. The inclusion criteria are based on a variety of factors such as the strength of a company’s technology, partnerships, venture backers and competitive market position.

The Fierce 15 celebrates the spirit of being “fierce”—championing innovation and creativity, even in the face of intense competition. A complete list of “Fierce 15” companies—the online newsletter’s ninth annual selection—is available online at http://www.fiercebiotech.com.

As part of this FierceBiotech recognition, Dr. Fetzer will be a member of the “Fierce 15 Revealed” panel, moderated by FierceBiotech editor John Carroll, which will discuss the success factors in securing financing in a challenging economic environment. The panel discussion will take place, during the 2011 BioPharm America™ conference in Boston, on Wednesday, September 7, at 5:15 p.m., in the Commonwealth C conference room at the Westin Boston Waterfront Hotel.

In addition, in a separate executive presentation taking place on Friday, September 9, at 9:30 a.m. in the Otis room at the Westin Boston Waterfront Hotel, Dr. Fetzer will brief BioPharm America™ conference attendees on Cerulean’s partnering strategy and key opportunities.

About Cerulean Pharma Inc.

Cerulean Pharma Inc. is a clinical-stage company specializing in the design and development of tumor-targeted nanopharmaceuticals. Cerulean is applying its proprietary nanopharmaceutical platform technologies and specialized capabilities to advance a new class of therapeutic agents for diseases with unmet medical needs. With an initial focus in oncology, the Company's technology platform can be readily applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, Alexandria Real Estate Equities, and William H. Rastetter. Cerulean is located in Cambridge, Massachusetts. For more information, please visit the Company's website at http://www.ceruleanrx.com.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Sign up is free at http://www.fiercebiotech.com.



CONTACT:

Schwartz Communications
Benjamin Navon or Kathy Vigneault, +1 781-684-0770
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Technology  Nanotechnology  Health  Biotechnology  Pharmaceutical  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.